,,ii  #aae? ,,congress  #a/ ,session    
,s4 #ajdi  ,,9 ,,! ,,s5ate ,,( ,,!      
,,unit$ ,,/ates  ,may #d1 #bjag,ms4     
,hassan 7= h]self & ,mr4 ,"y7 introduc$ 
! foll[+ bill2 :i* 0 read twice & ref]r$
 to ! ,committee on ,heal?1 ,education1 
,labor1 & ,p5sions  ,a ,,bill  ,to all[ 
! ,secret>y ( ,heal? & ,human ,s]vices  
to require t risk evaluation &          
mitigation /rategies = c]ta9 drugs      
include communication plans t provide   
in=mation ab\t drug =mulations or       
prop]ties describ$ 9 ! drug label+4  #a4
 ,%ort title ,?is ,act may be cit$ z !  
,opioid ,addiction ,risk ,transp>5cy    
,act4  #b4 ,,rems communication plans   
,section #eje-a7;e77#c7 ( ! ,f$]al      
,food1 ,drug1 & ,cosmetic ,act 7#ba     
,u4,s4,c4 #cee-a7;e77#c77 is am5d$--    
7#a7 9 subp>agraph 7,b71 by /rik+ 2 or2 
7#b7 9 subp>agraph 7,c71 by /rik+ !     
p]iod & ins]t+ 2 or2 &  7#c7 by add+ at 
! end ! foll[+3  7,d7 dissem9at+        
in=mation to heal? c>e provid]s ab\t !  
mean+ ( t]ms relat$ to drug =mulations  

or prop]ties t are describ$ 9 ! drug    
label+1 includ+ in=mation ab\t !        
limitations or pati5t c>e implications (
 su* =mulations or prop]ties1 & h[ su*  
=mulations or prop]ties may be relat$ to
 s]i\s adv]se drug ev5ts associat$ ) use
 ( ! drug4  4